Navigation Links
Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Date:9/17/2007

NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce three Clinical Data Focused conferences which cover many of the leading issues that are impacting the pharmaceutical industry today. These events offer educational and networking opportunities for Clinical, R&D, Regulatory and Medical Affairs executives from large to small pharmaceutical, biotech, device and medical technology companies.

Listed below are details on some of the featured events and highlights from those conferences:

October 15-16, San Francisco, CA

2nd Data Monitoring Committees/DSMBs Conference -- Evaluating Trial Safety

and Efficacy through Independent Examination of Interim Clinical Data

Following a successful inaugural DMC conference in February of 2007, where over 100 industry experts gathered in Philly, ExL Pharma is proud to announce the 2nd DMC conference taking place October 15-16 in San Francisco where the industry will once again gather to evaluate trial safety and efficacy through independent examination of interim clinical data. Hear case study examples from GSK, AstraZeneca, Genentech, Amgen and join the industry's leading authorities on Drug Safety, Regulatory Affairs and Biostatistics to discuss experiences, strategies and best practices for working with DMCs and incorporating them into clinical trial designs to mitigate risk, optimize resource allocation, reassure study integrity and increase safety.

November 5-6, Arlington, VA

Pediatric Clinical Trials Conference -- Increasing Efficiency in Drug

Development by Redefining Global Regulation and Identifying Trial

Enhancements

Featuring roundtable discussions chaired by Dean Steven Spielberg from Dartmouth Medical School; topics lead by experts in each field include CNS/Psychiatry, Infectious Disease, Oncology, Gastroenterology, and Geographic Study Differences. Other event presentations include NICHD perspective on Best Pharmaceuticals for Children Act, changes in pediatric regulatory landscape, and industry sponsored research.

December 3-4 2007, Philadelphia, PA

Pharmacovigilance Summit 2007 -- Developing and Implementing Compliant

Strategies to Minimize the Risk of Adverse Drug Reactions and Increase

Drug Safety

The only conference focusing on developing and implementing compliant strategies to minimize the risk of adverse drug reactions and increase drug safety. AstraZeneca, Cephalon Inc, Intermune, Sunesis Pharmaceuticals and more discuss practical crisis management and communications strategies, measuring the effectiveness of your pharmacovigilance efforts, and evaluating the effectiveness of your risk management plans and tools and more. Pre-conference workshop on The Impact of Regulation on Drug Safety.

To view our full list of upcoming conferences and webinars and details on our expert speaking faculties or to REGISTER, Log onto: http://www.exlpharma.com.

*Please mention Registration Code: ECL913 when registering

About ExL

ExL Pharma, a division of ExL Events, Inc., is an emerging leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.


'/>"/>
SOURCE ExL Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharma majors gear to supply anti-anthrax drug
2. First Artificial Heart patient has Major setback
3. Allergies: A major health problem
4. Animal insulin product to be discontinued by drug major Eli Lilly
5. Vision Loss Due To Diabetic Retinopathy a Major Cause Of Concern
6. Depression Found To Be A Major Cause for Death in Elderly
7. Genetics Has A Major Role To Play In Body Shape.
8. “Yes, I need Cosmetic surgery” – view of majority wome
9. Pigs Population A Major Threat To Encephalitis Ravaged UP
10. Unsafe Injections and Unclean Hand hygiene major cause of hospital infections in India
11. Delhi Government To Interlink All Major Hospitals Through e-Governance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for the ... active alerts and even taking an EKG from the watch while sharing these ...
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... 'Tis ... can disrupt daily routines. That means it's also the season when eating healthy, staying ... living with diabetes) on schedule is harder to do. , "Shopping trips, parties ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life ... story of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted ... looking for creative outlets, Carolyn gravitated toward writing through the inspiration of her ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to ... from clip to clip with high quality 4K lens flare footage," said Christina Austin ... lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Viking Therapeutics, ... clinical-stage biopharmaceutical company focused on the development of ... announced that the U.S. Food and Drug Administration ... for the treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 ... (TRß) agonist that selectively regulates the expression of ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... of 340B (AIR 340B) projects the 340B Drug Pricing Program ... by which time it is expected to exceed $23 billion ... would see 340B purchases surpass current Medicare Part B drug ... The new study – based on analysis of data on ...
(Date:12/6/2016)... , Dec. 6, 2016  BioAtla, LLC, ... development of Conditionally Active Biologic (CAB) antibody ... Sinobioway Group Company, Limited (Sinobioway) selected their ... The specific program candidates and the targeted ... BioAtla and Sinobioway entered into a strategic ...
Breaking Medicine Technology: